Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine

Psychopharmacology

Volumn 128, Issue 4, 1996, Pages 398-407

  Von Moltke, Lisa L ^a   Greenblatt, David J ^a   Duan, Su Xiang ^a   Schmider, Jürgen ^a   Kudchadker, Leena ^a   Fogelman, Steven M ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

naphthoflavone; cytochrome P450 1A2; in vitro metabolism; phenacetin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 HYDROXYNEFAZODONE; ALPHA NAPHTHOFLAVONE; CIMETIDINE; CYTOCHROME P450 ISOENZYME; DESVENLAFAXINE; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; FURAFYLLINE; HYDROXYNEFAZODONE; KETOCONAZOLE; N DESMETHYLVENLAFAXINE; NEFAZODONE; NORFLUOXETINE; NORSERTRALINE; PARACETAMOL; PAROXETINE; PHENACETIN; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DEALKYLATION; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOTRANSFORMATION; CYCLOHEXANOLS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; PHENACETIN; SEROTONIN UPTAKE INHIBITORS; TRIAZOLES;

EID: 0029853923     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050149     Document Type: Article

References (85)

1. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36: 521 530
2. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994a) Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37: 597 604
3. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994b) Diazepam metabolism by human liver microsomes is mediated by both S-mephenyloin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 37:131 137
4. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25: 261-270
5. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS (1995) Coadministration of nefazodone and benzodiazepines: II. A pharmaeokinetic interaction study with triazolam. J Clin Psychopharmacol 15: 320-326
6. Bergstrom RF, Peyton AL, Lemberger L (1992) Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51:239-248
7. Bertilsson L, Carrillo JA, Dahl M-L, Llerena A, Alm C, Bondesson U, Lindstrom L, de la Rubia IR, Ramos S, Benitez J (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473
8. Boobis AR, Kahn GC, Whyte C, Brodie MJ, Davies DS (1981) Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochem Pharmacol 30:2451 2456
9. Bourrié M, Meunier V, Berger Y, Fahre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277: 321-332
10. Brosen K (1995) Drug interactions and the cytochrome P450 system: the role of cytochrome P450 1A2. Clin Pharmacokinet 29 [suppl. 1]: 20 25
11. Brøsen K, Skjelbo E (1991) Fluoxetine and nor fluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 32: 136-137
12. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF (1993a) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44: 349-355
13. Brøsen K, Skjelbo E, Rasmussen RB, Poulsen HE, Loft S (1993b) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214
14. Chang T, Levine M, Bellward GD (1992) Selective inhibition of rat hepatic microsomal cytochrome P-450. II. Effect of the in vitro administration of cimetidine. J Pharmacol Exp Ther 260: 1450 1455
15. Chang TKH, Gonzalez FJ, Waxman DJ (1994) Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311: 437 442
16. Ciraulo DA, Shader RI (1990) Fluoxetine drug-drug interactions. J Clin Psychopharmacol 10:48-50, 213-217
17. Clarke SE, Ayrton AD, Chenery RJ (1994) Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24: 517 526
18. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective scrotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262 265
19. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, AbiDargham A, Shoaf S, Egan M, Elkashef A, Liboff S, Linnoila M (1994) Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 14: 340-343
20. Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057-9067
21. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD (1990) Nefazodone: preclinical pharmacology of a new anti depressant. Psychopharmacol Bull 26: 311-315
22. El-Yazigi A, Chaleby K, Gad A, Raines DA (1995) Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol 35:17 21
23. Fleishaker JC, Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46:35 39
24. Fleming CM, Branch RA, Wilkinson GR, Guengerich FP (1992) Human liver microsomal N-hydroxylalion of dapsone by cytochrome P-4503A4. Mol Pharmacol 41:975 980
25. Fogelman S, Schmider J, Greenblatt DJ, Shader RI (1995) Metabolism of venlafaxine: the role of P450 isoforms (abstract). J Clin Pharmacol 35:936
26. Gerber MC, Tejwani GA, Gerber N, Bianchine JR (1985) Drug interactions with cimetidine: an update. Pharmacol Ther 27: 353 370
27. Gonzalez FJ, Gelboin HV (1994) Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26:165-183
28. Greenblalt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS (1992) Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 52:479-486
29. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH (1995) Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15:399-408
30. Halpert JR (1995) Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 35:29 53
31. Halpert JR, Guengerich FP, Bend JR, Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125: 163 175
32. Holliday SM, Ben field P (1995) Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 49:280 294
33. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479
34. Jensen KG, Poulsen HE, Doehmer J, Loft S (1995) Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. Pharmacol Toxicol 76:286-288
35. Kadlubar FF (1994) Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 pheno typing and genotyping in humans. Drug Metab Rev 26: 37 46
36. Kunze KL, Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649 656
37. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ (1991) Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 104:323-327
38. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF (1988) The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 43:412-419
39. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP (1993) Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 43:827 832
40. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH (1994) Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 22:304-311
41. Murray M, Reidy GF (1990) Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 42:85 101
42. Newton DJ, Wang RW, Lu AYH (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154 158
43. Ohmori S, Takeda S, Rikihisa T, Kiuchi M, Kanakubo Y, Mitsukazu M (1993) Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol Pharm Bull 16:571 575
44. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2F1. Pharmacogenetics 5:143 150
45. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM (1993) Inhibition by fluoxetine of cytochrome P450 2D6 activity, Clin Pharmacol Ther 53:401 409
46. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalyzed by CYP2D6. Br J Clin Pharmacol 41:149 156
47. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez EJ, Guengerich FP, Yang CS (1993) Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics, Chem Res Toxicol 6:511 518
48. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers, Clin Pharmacol Ther 56:471 476
49. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK (1995) Metabolism and bioactivalion of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984 990
50. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14:90 98
51. Rasmussen BB, Mäcnpää J, Pelconen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Phamacol 39:151 159
52. Ring BJ, Binkley SN, Roskos L, Wrighton SA (1995) Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed I'-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 275:1131 1135
53. Sarkar MA, Jackson BJ (1994) Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 22:827 834
54. Schmider J, Greenblatl DJ, von Moltke LL, Harmatz JS, Shader RI (1995) N-Demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 275:592 597
55. Schmider J, Greenblatl DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D, Shader RI (1996a) Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology 52:125 134
56. Sehmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1996b) inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 41:339 343
57. Schwab GE, Raucy JL, Johnson EE (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthollavone. Mol Pharmacol 33:493 499
58. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldslein JA (1993) Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3:239 249
59. Sesardic D, Boobis AR, Edwards RJ, Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26:263 372
60. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651 663
61. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450 6455
62. Sicss M-H, Leclere J, Canivene-Lavier M-C, Rat P, Suschetet M (1995) Heterogenous effects of natural flavonoids on monooxygenase activities in human and rat liver microsomes. Toxicol App Pharmacol 130:73 78
63. Skjelbo E, Brosen K (1992) Inhibitors of imipramino metabolism by human liver microsomes. Br J Clin Pharmacol 34:256 261
64. Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK (1995) Determination of human hepatic cytochrome P4501A2 activity in vitro: use of tacrine as an isoenzymespecific probe. Drug Metab Dispos 23:929 934
65. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP (1993) Effect of fluvoxamino on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243 246
66. Tarrus E, Cami J, Roberts DJ, Spickett RGW, Celdran E, Segura J (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9 18
67. Tassaneeyakul W, Mohamed Z, Birken DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez EJ, Miners JO (1992) Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and micorsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173 183
68. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401 407
69. Tassaneeyakul W, Birkelt DJ, Veronese ME, McManus ME, Tukey RH, Miners JO (1994a) Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2, Pharmacogenetics 4:281 284
70. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, Miners JO (1994b) Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1, and 3A isoforms. Biochem Pharmacol 47:1767 1776
71. Tjia JE, Colbert J, Back DJ (1996) Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 276:912 917
72. Tröger U, Meyer FP (1995) Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Clin Pharmacokinet 28:287 314
73. van Laar MW, Willigenburg APP, Volkerts ER (1995) Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 15:30 40
74. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI (1993) Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47: 268 276
75. von Moltke LL, Greenblatt DJ, Cotrcau-Bibbo MM, Duan SX, Harmatz JS, Shader RI (1994a) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278 1283
76. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994b) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepres sants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23 31
77. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI (1994c) Cytochromes in psychopharmacology. J Clin Psychopharmacol 14:1 4
78. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995a) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125- 131
79. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1995b) Metabolism of drugs by Cytochrome P450-3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokin 29 [suppl. 1]:33-43
80. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI (1996a) Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 16:104 112
81. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI (1996b) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370 379
82. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1996c) Nefazodone in vitro: metabolic conversions, and inhibition of P450-3A isoforms (abstract). Clin Pharmacol Ther 59:176
83. Wrighton SA, Ring BJ (1994) Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole. nifedipine, erythromycin, cimetidine. and nizatidine. Pharm Res 11:921-924
84. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ (1993) In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 25:453 484
85. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, Shimada T (1994) Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 46:568 577